Bioray closes enrollment in BRL-101 gene-editing trial for beta-thalassemia
The Phase 1/2 trial moved to Active, not recruiting with 39 patients dosed, setting up a safety and engraftment readout that will test China's homegrown answer to Vertex's exa-cel.
Executive Summary
- Bioray Laboratories' Phase 1/2 gene-editing trial for transfusion-dependent beta-thalassemia stopped recruiting after enrollment grew well beyond its original target, moving the study into its follow-up and data-collection stage.
- The trial is built to answer a safety and engraftment question, not a head-to-head efficacy claim, and its primary completion date has been pushed back twice as the sponsor worked through age-group cohorts.
- BRL-101 sits in a small field of gene-edited therapies for beta-thalassemia that includes Vertex's already-approved exa-cel and two other China-based programs still in early testing, none of which have posted resolved outcomes yet.
- A clean safety and engraftment result would support the broader case that CRISPR-based beta-globin editing can reproduce the results already achieved by gene-edited approaches with a different molecular target.
The status change
ClinicalTrials.gov recorded the trial's status change to Active, not recruiting on July 21, 2026, ending an enrollment period that began in November 2022. The registry update also pushed the primary completion date to October 20, 2026, from August 20, 2026. The trial is testing BRL-101, a CD34-positive autologous hematopoietic stem cell product edited at the BCL11A enhancer site and delivered as a single intravenous infusion, in patients with beta-thalassemia major across seven sites in China. NCT05577312+1Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaNCT05577312Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaJul 21, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Enrollment and the primary bar
Enrollment grew from a target of 9 to 39 patients as recorded in the January 2026 registry update, a fourfold increase that reflects a Phase 1/2 design expanding across age cohorts rather than a troubled trial. The trial tests three primary endpoints: the frequency and severity of adverse events over 12 months following infusion, the proportion of patients who achieve stem cell engraftment, and time to neutrophil engraftment, defined as an absolute neutrophil count of at least 0.5x10^9/L for three consecutive days within 42 days of infusion. None of these results have posted to the registry. NCT05577312Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaNCT05577312
The competitive field
Vertex Pharmaceuticals' exagamglogene autotemcel is approved for transfusion-dependent beta-thalassemia and uses a different molecular target, BCL11A, rather than the beta-globin gene itself that BRL-101 edits directly. The closest direct comparator on record is Kamau Therapeutics' nula-cel, a Phase 1/2 gene-correction therapy for sickle cell disease that also targets the beta-globin gene, though in a different indication. Two other China-based programs, Kanglin Biotechnology's KL003 and CorrectSequence Therapeutics' CS-101, are also testing beta-globin-directed cell therapies in beta-thalassemia at earlier phases.
What the readout will test
With no comparator arm and an open-label, single-arm design, the trial can establish tolerability and engraftment kinetics for direct beta-globin editing, not a comparative efficacy claim against Casgevy's BCL11A-editing approach. Given that Casgevy has already established that gene editing in autologous stem cells can achieve transfusion independence in this disease, the informative outcome from BRL-101 would be a safety and engraftment profile that tracks the same result using an edit at the beta-globin gene itself rather than its regulator. NCT05577312Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaNCT05577312
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.